Chinese Medical Sciences Journal ›› 2011, Vol. 26 ›› Issue (2): 113-118.doi: 10.1016/S1001-9294(11)60030-8
• Original Article • Previous Articles Next Articles
Application of Positron Emission Tomography Molecular Probes in Hepatocellular Carcinoma Biological Imaging
Ting-ting He, and Jia-he Tian*
- Department of Nuclear Medicine, General Hospital of the Chinese People’s Liberation Army, Beijing 100853, China
-
Received:2010-11-07Revised:2011-06-24Online:2011-06-24Published:2011-06-24
Cite this article
Ting-ting He, and Jia-he Tian*. Application of Positron Emission Tomography Molecular Probes in Hepatocellular Carcinoma Biological Imaging[J].Chinese Medical Sciences Journal, 2011, 26(2): 113-118.
share this article
Add to citation manager EndNote|Reference Manager|ProCite|BibTeX|RefWorks
| 1. | Delbeke D,Martin WH,Sandler MP,et al. Evaluation of benign vsmalignant hepatic lesions with positron emission tomography. Arch Surg 1998; 133:510-6. |
| 2. | Yun M, Bang SH, Kim JW, et al. Theimportance of acetyl coenzyme A synthetase for11C -acetate uptake and cell survival inhepatocellular carcinoma. J Nucl Med 2009; 50:1222-8. |
| 3. | Park JW, Kim JH, Kim SK, et al. Aprospective evaluation of18F -FDGand11C -acetatePET/CT for detection of primary and metastatic hepatocellular carcinoma. J NuclMed 2008; 49:1912-21. |
| 4. | Ho CL, Yu SC, Yeung DW.11C -acetate PET imaging inhepatocellular carcinoma and other liver masses. J Nucl Med 2003; 44:213-21. |
| 5. | Yamamoto Y, Nishiyama Y, Kameyama R, et al. Detectionof hepatocellular carcinoma using11C -cholinePET: comparison with18F -FDGPET. J Nucl Med 2008; 49:1245-8. |
| 6. | Warburg O,Posener K, Negelein E. On the metabolism of cancer cells. BiochemischeZeitschrift 1924; 152:319-44. |
| 7. | Salem N, MacLennan GT, Kuang Y, et al.Quantitative evaluation of 2-deoxy-2[F-18]fluoro-D-glucose-positron emissiontomography imaging on the woodchuck model of hepatocellular carcinoma withhistological correlation. Mol Imaging Biol 2007; 9:135-43. |
| 8. | Trojan J, Schroeder O, Raedle J, et al. Fluorine-18FDGpositron emission tomography for imaging of hepatocellular carcinoma. Am JGastroenterol 1999; 94:3314-9. |
| 9. | Torizuka T,Tamaki N,Inokuma T,et al. In vivo assessment of glucosemetabolism in hepatocellular carcinoma with FDG-PET. J Nucl Med 1995;36:1811-7. |
| 10 | Smeets P,Ham H, Ceelen W,et al. Differentiation between peri-anastomotic inflammatory changes and localrecurrence following neoadjuvant radiochemotherapy surgery for colorectalcancer using visual and semiquantitative analysis of PET-CT data. Q J Nucl Med Mol Imaging2010; 4:327-32. |
| 11 | Kong YH,Han CJ,Lee SD,et al. Positron emission tomography with fluorine-18-fluorodeoxyglucose isuseful for predicting the prognosis of patients with hepatocellular carcinoma.Korean J Hepatol 2004; 10:279-87. |
| 12 | Hatano E,Ikai I, Higashi T, et al. Preoperativepositron emission tomography with fluorine-18-fluorodeoxyglu- cose ispredictive of prognosis in patients with hepatocellular carcinoma afterresection. World J Surg 2006; 30:1736-41. |
| 13 | Yang SH, Suh KS,Lee HW, et al. The role of 18F-FDG-PETimaging for the selection of liver transplantation candidates amonghepatocellular carcinoma patients. Liver Transpl 2006; 12:1655-60. |
| 14 | Wolfort RM, Papillion PW, Turnage RH, et al. Role ofFDG-PET in the evaluation and staging of hepatocellular carcinoma withcomparison of tumor size, AFP level, and histologic grade. Int Surg 2010;95:67-75. |
| 15 | Lee JW, Paeng JC, Kang KW, et al. Predictionof tumor recurrence by18F -FDGPET in liver transplantation for hepatocellular carcinoma. J Nucl Med 2009;50:682-7. |
| 16 | Higashi T, Hatano E, Ikai I, et al. FDG PET asa prognostic predictor in the early post-therapeutic evaluation forunresectable hepatocellular carcinoma. Eur J Nucl Med Mol Imaging 2010;37:468-82. |
| 17 | Kornberg A, Küpper B, Thrum K, et al. Increased18F -FDG uptake ofhepatocellular carcinoma on positron emission tomography independently predictstumor recurrence in liver transplant patients. Transplant Proc 2009; 41:2561- 3. |
| 18 | Kornberg A, Freesmeyer M, B?rthel E, et al.18F -FDG- uptake ofhepatocellular carcinoma on PET predicts microvascular tumor invasion in livertransplant patients. Am J Transpl2009; 9:592-600. |
| 19 | Ong LC, Jin Y, Song IC, et al. 2-[ 18F ]-2-deoxy-D-glucose (FDG)uptake in human tumor cells is related to the expression of GLUT-1 andhexokinase II. Acta Radiol 2008; 49:1145-53. |
| 20 | Paudyal B, Paudyal P, Oriuchi N, et al. Clinicalimplication of glucose transport and metabolism evaluated by18F -FDG PET in hepatocellularcarcinoma. Int J Oncol 2008; 33:1047-54. |
| 21 | Paudyal B, Oriuchi N, Paudyal P, et al. Clinicopathologicalpresentation of varying18F -FDGuptake and expression of glucose transporter 1 and hexokinase II in cases ofhepatocellular carcinoma and cholangiocellular carcinoma. Ann Nucl Med 2008;22:83-6. |
| 22 | Ahn KJ, Hwang HS, Park JH, et al. Evaluationof the role of hexokinase type II in cellular proliferation and apoptosis usinghuman hepatocellular carcinoma cell lines. J Nucl Med 2009; 50:1525-32. |
| 23 | Zhao S, Kuge Y, Mochizuki T, et al.Biologic correlates of intratumoral heterogeneity in18F -FDG distribution with regionalexpression of glucose transporters and hexo- kinase-II in experimental tumor. JNucl Med 2005; 46:675-82. |
| 24 | Seo S, Hatano E, Higashi T, et al.P-glycoprotein expression affects18F -fluorodeoxyglucoseaccumulation in hepatocellular carcinoma invivo andin vitro. Int J Oncol2009; 34:1303-12. |
| 25 | Oyama N,Akino H, Kanamaru H, et al. 11 C-acetate PETimaging of prostate cancer. J Nucl Med 2002; 43:181-6. |
| 26 | YoshimotoM, Waki A, Yonekura Y, et al. Characterization of acetatemetabolism in tumor cells in relation to cell proliferation: acetate metabolismin tumor cells. Nucl Med Biol 2001; 28:117-22. |
| 27 | Vāvere AL,Kridel SJ,Wheeler FB,et al.1 -11C -acetateas a PET radiopharmaceutical for imaging fatty acid synthase expression inprostate cancer. J Nucl Med 2008; 49:327- 34. |
| 29 | Salem N, Kuang Y, Corn D, et al. [(Methyl)1- 11C ]-acetatemetabolism in hepatocellular carcinoma. Mol Imaging Biol 2011; 13:140-51. |
| 30 | Hwang KH, Choi DJ, Lee SY, et al. Evaluationof patients with hepatocellular carcinomas using [ 11C ]acetate and [ 18F ]FDG PET/CT: a preliminary study. Appl Radiat Isot 2009; 67:1195-8. |
| 31 | Ho CL, Chen S, Yeung DW, et al. Dual-tracer PET/CTimaging in evaluation of metastatic hepatocellular carcinoma. J Nucl Med 2007;8:902-9. |
| 32 | Clarke DD.Fluoroacetate and fluorocitrate: mechanism of action. Neurochem Res 1991;16:1055-8. |
| 33 | Ponde DE, Dence CS, Oyama N, et al.18F -fluoroacetate: a potentialacetate analog for prostate tumor imaging-- invivo evaluation of18F -fluoroacetateversus11C -acetate.J Nucl Med 2007; 48:420-8. |
| 34 | Marik J, Ogasawara A, Martin-McNulty B, et al.PET of glial metabolism using 2 -18F -fluoroacetate.J Nucl Med 2009; 50:982-90. |
| 35 | Roivainen A, Forsback S, Gr?nroos T, et al. Blood metabolismof [methyl -11C ]choline; implicationsforin vivo imaging with positronemission tomography. Eur J Nucl Med 2000; 27:25-32. |
| 36 | Fallanca F, Giovacchini G, Picchio M, et al.Incidental detection by [ 11C ]cholinePET/CT of meningiomas in prostate cancer patients. Q J Nucl Med Mol Imaging2009; 53:417-21. |
| 37 | Kato T, Shinoda J, Nakayama N, et al.Metabolic assessment of gliomas using11C -methionine,[ 18F ]- fluorodeoxyglucose,and11C -cholinepositron-emission tomography. AJNR Am J Neuroradiol 2008; 29:1176-82. |
| 38 | Castellucci P,Fuccio C,Rubello D,et al. Is there a role for (11)C-choline PET/CT in the early detection ofmetastatic disease in surgically treated prostate cancer patients with a mildPSA increase 11C -methionine for differentiating tumors from granulomas in experimental ratmodels: a comparison with18F -FDGand18F -FLT. JNucl Med 2008; 49:135-41. |
| 41 | Rasey JS,Grierson JR, Wiens LW, et al. Validation of FLT uptake as a measure ofthymidine kinase-1 activity in A549 carcinoma cells. J Nucl Med 2002;43:1210-7. |
| 42 | FrancisDL, Freeman A, Visvikis D, et al. In vivoimaging of cellular proliferation in colorectal cancer using positron emissiontomography. Gut 2003; 52:1602-6. |
| 43 | vanWestreenen HL, Cobben DC, Jager PL, et al. Comparison of18F -FLT PET and18F -FDG PET in esophagealcancer. J Nucl Med 2005; 46:400-4. |
| 44 | Smyczek-GargyaB, Fersis N, Dittmann H, et al. PET with [ 18F ]fluorothymidinefor imaging of primary breast cancer: a pilot study. Eur J Nucl Med Mol Imaging2004; 31:720-4. |
| 45 | Cobben DC, van der Laan BF, Maas B, et al.18F -FLT PET for visualization of laryngealcancer: comparison with18F -FDGPET. J Nucl Med 2004; 45:226-1. |
| 46 | Buck AK,Halter G, Schirrmeister H, et al. Imaging proliferation in lung tumors withPET:18F -FLT versus18F -FDG. J Nucl Med 2003; 44:1426-31. |
| 47 | VesselleH, Grierson J, Muzi M, et al. In vivovalidation of3’ deoxy -3’ -[ 18F ]fluorothymidine([ 18F ]FLT) as aproliferation imaging tracer in humans: correlation of [ 18F ]FLT uptake by positron emissiontomography with Ki-67 immunohistochemistry and flow cytometry in human lungtumors. Clin Cancer Res 2002; 8:3315-23. |
| 48 | Buck AK,Schirrmeister H, Hetzel M, et al. 3-deoxy- 3-[ 18F ]fluorothymidine-positron emissiontomography for noninvasive assessment of proliferation in pulmonary nodules.Cancer Res 2002; 62:3331-4. |
| 49 | Yap CS,Czernin J, Fishbein MC, et al. Evaluation of thoracic tumors with18F -fluorothymidine and18F -fluorodeoxyglucose-positron emissiontomography. Chest 2006; 129:393-401. |
| 50 | Eckel F, Herrmann K, Schmidt S, et al. Imagingof proliferation in hepatocellular carcinoma with the in vivo marker18F -fluorothymidine.J Nucl Med 2009; 50:1441-7. |
| 51 | Brizel DM,Sibley GS, Prosnitz LR, et al. Tumor hypoxia adversely affects the prognosis ofcarcinoma of the head and neck. Int J Radiat Oncol Biol Phys 1997; 38:285-9. |
| 52 | Gagel B,Reinartz P,Demirel C,et al. [ 18F ] fluoromisonidazoleand [ 18F ] fluorodeoxyglucosepositron emission tomography in response evaluation after chemo-/ radiotherapyof non-small-cell lung cancer: a feasibility study. BMC Cancer2006; 6:51. |
| 53 | Chao KS, Bosch WR, Mutic S, et al. A novel approach to overcomehypoxic tumor resistance: Cu-ATSM-guided intensity-modulated radiation therapy.Int J Radiat Oncol Biol Phys 2001; 49:1171-82. |
| 54 | Rischin D,Hicks RJ, Fisher R, et al. Prognostic significance of [ 18F ]-misonidazole positron emission tomography-detectedtumor hypoxia in patients with advanced head and neck cancer randomly assignedto chemoradiation with or without tirapazamine: a substudy of Trans- TasmanRadiation Oncology Group Study 98.02. J Clin Oncol 2006; 24:2098-104. |
| 55 | Riedl CC,Brader P,Zanzonico P,et al. Tumor hypoxia imaging in orthotopic liver tumors and peritoneal metastasis:a comparative study featuring dynamic18F -MISO and 124I-IAZG PET in the same study cohort. Eur J Nucl Med Mol Imaging2008; 35:39-46. |
| 56 | Ziemer LS, Evans SM, Kachur AV, et al.Noninvasive imaging of tumor hypoxia in rats using the 2-nitroimidazole18F -EF5. Eur J Nucl Med Mol Imaging 2003;30:259-66. |
| 57 | Cai W, Chen K, Li ZB, et al.Dual-function probe for PET and near-infrared fluorescence imaging of tumorvasculature. J Nucl Med 2007; 48:1862-70. |
| 58 | Yan Y, Chen K, Yang M, et al. A new18F -labeled BBN-RGD peptideheterodimer with a symmetric linker for prostate cancer imaging. Amino Acids2010 Oct. [cited 2010 Oct 5]. Available from: http://www.springerlink.com/content/al642447583u8p 4l / |
| 59 | Zhao H, Wang JC, Sun QS, et al. RGD-basedstrategies for improving antitumor activity of paclitaxel-loaded liposomes innude mice xenografted with human ovarian cancer. J Drug Target 2009; 17:10-8. |
| 60 | Scheer MG,Stollman TH, Boerman OC, et al. Imaging liver metastases of colorectal cancerpatients with radiolabelled bevacizumab: lack of correlation with VEGF-Aexpression. Eur J Cancer 2008; 44:1835-40. |
| 61 | Schmidt K, Hoffend J, Altmann A, et al. TroponinI overexpression inhibits tumor growth, perfusion, and vascularization of morrishepatoma. J Nucl Med 2006; 47: 1506-14. |
| 62 | Kawamura K, Kubota K, Kobayashi T, et al.Evaluation of [ 11C ]SA5845and [ 11C ]SA4503 for imagingof sigma receptors in tumors by animal PET. Ann Nucl Med, 2005; 19:701-9. |
| 63 | Aloya R,Shirvan A, Grimberg H, et al. Molecular imaging of cell deathin vivo by a novel small moleculeprobe. Apoptosis 2006; 11:2089-101. |
| 64 | Toretsky J,Levenson A,Weinberg IN,et al. Preparation of F-18 labeled annexin V: a potential PET radiopharmaceuticalfor imaging cell death. Nucl Med Biol 2004; 31: 747-52. |
| *Corresponding author Tel: 86-10-66936429, Fax:86-10-68161853, E-mail: tianjh@vip.sina.com | |
| △Supported by National Natural ScienceFoundation of China (30770607). |
| [1] | Xu Yanhong,Yang Jia,Meng Jie,Wang Han. Targeted MR Imaging Adopting T1-Weighted Ultra-Small Iron Oxide Nanoparticles for Early Hepatocellular Carcinoma: An in vitro and in vivo Study [J]. Chinese Medical Sciences Journal, 2020, 35(2): 142-150. |
| [2] | Zhang Xiufen, Yu Bo, Zhang Fuzheng, Guo Zijian, Li Lihua. microRNA-18a Promotes Cell Migration and Invasion Through Inhibiting Dicer l Expression in Hepatocellular Carcinoma In Vitro△ [J]. Chinese Medical Sciences Journal, 2017, 32(1): 34-43. |
| [3] | Jian-bo Xu, Gang Xu, Guo-feng Chen, Dian-hua Gu, Jian-huai Zhang, Fu-zhen Qi*. Hepatocellular Carcinoma with Hypersplenic Thrombocytopenia and Situs Inversus Totalis: A Case Report [J]. Chinese Medical Sciences Journal, 2016, 31(2): 134-136. |
| [4] | Ye Jin, Li Zhou, Ke-min Jin, and Bao-cai Xing. Expression of Plasminogen Activator Inhibitor-2 is Negatively Associated with Invasive Potential in Hepatocellular Carcinoma Cells△ [J]. Chinese Medical Sciences Journal, 2013, 28(1): 16-19. |
| [5] | Yao Zhang, Hua Zhang, Au Elizabeth, Xiao-qing Liu. Epidemiology of Hepatitis B and Associated Liver Diseases in China [J]. Chinese Medical Sciences Journal, 2012, 27(4): 243-248. |
| Viewed | ||||||
|
Full text |
|
|||||
|
Abstract |
|
|||||
|
